NT5E and neoplasm: The above indicates that activation of A3, A2A or A1 adenosine receptors is able to inhibit tumor growth only at its early stage, but at the more advanced stage proliferative activity of agonist-stimulated tumors is at a comparable level to wild-type tumors with intact CD73 activity.